Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs 10X Genomics Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while 10X Genomics Inc trades at $72.37 (market cap $9.53B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 3.2× 10X Genomics Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| GEHC | TXG | |
|---|---|---|
Market Cap | $30.93B | $9.53B |
Volume | 5,033,451 | 4,138,224 |
Sector | Health | Health |
52-Week High | $88.16 | $97.74 |
52-Week Low | $59.48 | $11.83 |
Enterprise Value | $39.39B | $9.05B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 91 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
TXG (10x Genomics) trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with a significant reduction in net losses (-$43.54M in 2025 vs. -$183M in 2024) and positive operating cash flow of $136.05M. Recent news highlights strong demand for its new Atera spatial biology platform and a patent victory. However, valuation metrics remain elevated with a P/S of 14.86 and EV/EBITDA of 230.71.
The outlook is cautiously optimistic. Analyst consensus is mixed with a $83.30 price target implying 16% upside, but execution on Atera commercialization and sustained margin improvement are critical. Key risks include high valuation, competitive pressures, and reliance on instrument sales growth. The stock offers growth exposure to spatial biology but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
